influenza
one
commonest
infect
human
popul
infect
signific
percentag
popul
year
caus
substanti
morbid
mortal
global
season
influenza
import
caus
morbid
mortal
novel
influenza
viru
strain
emerg
potenti
caus
global
pandem
children
common
sourc
inluenza
transmiss
commun
form
import
risk
group
sever
influenza
ill
particularli
infant
children
underli
chronic
ill
influenza
virus
envelop
virus
famili
orthomyxovirida
influenza
neg
sens
rna
genom
divid
eight
segment
segment
genom
allow
exchang
gene
influenza
virus
type
genet
reassort
two
type
influenza
virus
influenza
b
caus
epidem
diseas
human
influenza
virus
divid
subtyp
influenza
b
virus
lineag
base
antigen
structur
influenza
subtyp
differenti
base
characterist
haemagglutinin
ha
neuraminidas
na
surfac
antigen
haemaglutinin
respons
viru
attach
earli
stage
infect
main
antigen
host
immun
respons
direct
neuraminidas
facilit
releas
matur
viru
cell
surfac
current
two
influenza
subtyp
influenza
influenza
two
influenza
b
lineag
yamagata
victoria
cocircul
global
human
popul
influenza
virus
least
ha
na
subtyp
isol
anim
bird
pig
hors
dog
mani
differ
ha
na
subtyp
circul
anim
anim
bird
pig
may
reservoir
emerg
influenza
viru
subtyp
infect
human
sever
subtyp
influenza
influenza
caus
sever
ill
even
death
individu
close
contact
anim
abl
effici
transmit
persontoperson
antigen
drift
emerg
new
influenza
viru
antigen
variant
result
point
mutat
recombin
occur
viral
replic
frequent
emerg
antigen
variant
contribut
season
influenza
epidem
lead
requir
annual
assess
need
updat
virus
includ
influenza
vaccin
antigen
shift
term
larger
genet
chang
occur
infrequ
influenza
virus
new
substanti
differ
influenza
viru
subtyp
emerg
human
potenti
caus
pandem
effici
transmit
human
presenc
littl
preexist
popul
immun
fig
estim
popul
becom
infect
influenza
year
develop
symptomat
ill
rate
influenza
infect
highest
children
age
year
annual
children
age
year
approxim
million
new
case
influenza
million
case
influenzaassoci
acut
lower
respiratori
tract
infect
alri
case
paediatr
alri
one
million
case
influenzaassoci
sever
alri
sever
alri
global
influenzaassoci
death
children
year
estim
occur
year
occur
develop
countri
influenza
associ
approxim
respiratori
hospit
children
year
worldwid
rang
children
age
month
children
age
year
influenzaassoci
hospit
rate
three
time
higher
develop
industrialis
countri
incid
mortal
associ
influenza
vari
substanti
yeartoyear
result
differ
circul
type
subtyp
differ
propens
caus
sever
ill
year
influenza
predomin
may
typic
associ
increas
risk
sever
diseas
peopl
age
may
develop
symptomat
influenza
infect
highest
rate
influenzaposit
influenzalik
ill
ili
seen
children
age
year
schoolag
children
import
sourc
infect
commun
influenza
outbreak
occur
school
influenza
season
influenza
season
influenza
import
caus
school
absente
ill
children
caus
substanti
econom
burden
result
caregiv
absente
work
care
ill
children
well
outpati
visit
children
lead
addit
antibiot
cours
prescrib
hospit
mortal
influenza
season
substanti
sever
influenza
season
larg
number
medic
care
visit
result
influenza
overwhelm
health
system
highest
rate
influenzaassoci
hospit
death
typic
seen
individu
age
year
year
underli
medic
condit
confer
increas
risk
sever
influenza
children
age
year
lesser
extent
age
year
increas
rate
influenzaassoci
hospit
mortal
compar
older
children
children
underli
ill
particularli
cardiac
respiratori
sever
neurolog
diseas
increas
risk
sever
outcom
associ
influenza
studi
south
africa
found
amongst
children
age
year
malnutrit
prematur
hiv
infect
associ
increas
odd
influenzaassoci
hospit
hivinfect
children
approxim
two
time
elev
risk
influenza
hospit
like
die
influenza
hospit
compar
hivuninfect
children
pregnant
women
increas
risk
sever
influenza
studi
suggest
influenza
pregnanc
may
associ
advers
outcom
infant
born
women
low
birth
weight
preterm
birth
stillbirth
other
disput
temper
climat
influenza
typic
caus
annual
season
epidem
winter
month
april
septemb
southern
hemispher
octob
april
northern
hemispher
tropic
climat
influenza
commonli
circul
yearround
two
peak
may
coincid
climat
event
raini
season
may
present
challeng
decisionmak
around
best
time
vaccin
vaccin
formul
northern
southern
hemispher
use
see
section
vaccin
start
peak
size
durat
influenza
season
may
vari
substanti
yeartoyear
season
influenza
give
rise
outbreak
close
set
school
occur
time
year
common
influenza
season
influenza
pandem
caus
emerg
spread
human
popul
new
influenza
viru
either
new
substanti
alter
ha
na
combin
littl
immun
human
easili
transmit
human
caus
clinic
ill
human
emerg
pandem
influenza
strain
unpredict
occur
two
mechan
firstli
host
could
simultan
infect
two
differ
influenza
viru
subtyp
could
allow
exchang
genet
materi
reassort
emerg
new
subtyp
exampl
could
occur
pig
infect
human
avian
origin
influenza
subtyp
simultan
genet
exchang
lead
emerg
viru
adapt
spread
human
ha
andor
na
current
circul
human
second
way
novel
subtyp
emerg
avian
anim
adapt
subtyp
directli
transmit
human
undergo
adapt
allow
transmiss
human
current
avian
influenza
viru
subtyp
influenza
transmit
human
usual
follow
close
contact
poultri
caus
sever
infect
howev
virus
adapt
effici
transmiss
person
person
therefor
given
rise
new
pandem
strain
global
surveil
new
influenza
viru
strain
essenti
earli
identif
novel
strain
allow
global
public
health
respons
pandem
influenza
wide
acknowledg
sever
recent
time
estim
million
death
worldwid
recent
pandem
asian
flu
hong
kong
flu
associ
lower
death
toll
characterist
pandem
influenza
strain
shift
age
distribut
death
predominantli
affect
extrem
age
young
infant
elderli
mortal
young
adult
age
year
although
influenza
pandem
caus
substanti
mortal
annual
cumul
death
year
associ
season
mortal
far
outweigh
burden
novel
influenza
viru
influenza
emerg
human
popul
caus
global
pandem
viru
antigen
distinct
viru
circul
human
popul
earli
thought
enter
human
popul
pig
henc
colloqui
name
swine
flu
overal
mortal
burden
strain
estim
death
global
similar
annual
mortal
burden
season
influenza
although
strain
exhibit
characterist
pandem
age
shift
disproportion
affect
individu
age
year
subsequ
influenza
circul
human
popul
immun
popul
built
influenza
becom
predomin
season
train
replac
previous
circul
behav
like
season
influenza
viru
influenza
predominantli
spread
persontoperson
larg
droplet
direct
contact
respiratori
secret
contribut
airborn
transmiss
unclear
incub
period
influenza
typic
rang
day
median
day
influenza
viru
typic
shed
nasopharynx
day
ill
viral
shed
may
longer
sever
ill
individu
young
children
immunocompromis
individu
reproduct
number
influenza
serial
interv
usual
estim
day
individu
suscept
infect
diseas
depend
host
characterist
includ
preexist
cellular
humor
immun
influenza
young
children
may
preexist
immun
influenza
older
children
adult
often
expos
circul
influenza
sever
time
may
also
pre
exist
immun
vaccin
natur
immun
fulli
protect
larg
variabl
influenza
ha
na
influenza
viru
replic
predominantli
occur
respiratori
tract
columnar
epitheli
cell
infect
lead
loss
cilia
cell
death
damag
respiratori
tract
well
immunolog
chang
lead
increas
suscept
bacteri
superinfect
viremia
influenza
rel
uncommon
although
constitut
symptom
promin
featur
clinic
diseas
influenza
season
influenza
consid
children
present
suggest
clinic
includ
alreadi
admit
hospit
nosocomi
transmiss
influenza
well
describ
influenza
still
consid
outsid
influenza
season
particularli
travel
children
resid
tropic
subtrop
climat
yearround
influenza
transmiss
occur
accur
clinic
diagnosi
influenza
challeng
particularli
younger
children
lack
specif
sign
symptom
result
patient
receiv
diagnos
influenzalik
ill
viral
upper
respiratori
tract
ill
unless
diagnost
test
undertaken
degre
diagnost
uncertainti
acknowledg
howev
sinc
case
selflimit
manag
larg
support
usual
need
obtain
precis
microbiolog
diagnosi
current
avail
diagnost
test
influenza
includ
follow
rapid
pointofcar
antigen
detect
test
number
differ
test
current
avail
although
remain
unavail
mani
set
provid
result
within
min
use
appropri
help
confirm
influenza
infect
gener
insuffici
sensit
reliabl
exclud
diseas
perform
depend
antigen
express
current
circul
strain
influenza
activ
low
posit
result
like
falseposit
howev
posit
predict
valu
improv
influenza
activ
increas
convers
period
high
influenza
activ
falseneg
like
may
warrant
addit
test
patientssinc
diagnost
confirm
seldom
affect
manag
children
use
test
gener
recommend
lowresourc
set
use
judici
betterresourc
area
use
clear
clinician
mind
result
go
alter
treatment
posit
result
potenti
reduc
antibiot
usag
allow
earli
use
antivir
high
risk
complic
sever
diseas
howev
import
recogn
identif
influenza
exclud
presenc
bacteri
coinfect
polymeras
chain
reaction
pcr
test
test
current
consid
reliabl
diagnosi
influenza
children
amongst
avail
option
sensit
specif
perform
respiratori
sampl
commonli
nasopharyng
aspir
swab
also
abl
differenti
influenza
b
well
subtyp
influenza
amor
recent
pointofcar
pcr
assay
becom
avail
develop
world
set
perform
nasal
swab
suppli
reliabl
result
littl
min
current
avail
develop
world
set
afford
could
becom
import
new
influenza
diagnosticsinc
live
attenu
influenza
vaccin
contain
influenza
genet
materi
recent
receipt
vaccin
also
result
posit
pcr
test
immunofluoresc
test
also
perform
nasal
nasopharyng
swab
allow
direct
indirect
detect
influenza
antigen
influenza
b
differenti
howev
sensit
test
moder
particularli
period
high
transmiss
neg
test
may
need
repeat
use
sensit
methodolog
pcr
cultur
viral
cultur
viral
cultur
take
least
hour
limit
util
routin
diagnosi
influenza
howev
help
part
surveil
activ
isol
use
inform
annual
vaccin
plan
serolog
assay
varieti
hemagglutinationinhibit
enzymelink
immunosorb
assay
elisa
complement
fixat
assay
serolog
assay
perform
limit
diagnost
valu
requir
acut
convalesc
sampl
fourfold
increas
titr
allow
retrospect
influenza
diagnosi
made
primari
role
research
tool
antivir
avail
specif
treatment
influenza
two
class
antiinfluenza
drug
avail
neuraminidas
inhibitor
eg
oseltamivir
zanamivir
inhibitor
eg
amantadin
rimantadin
class
inact
respiratori
virus
resist
emerg
circul
influenza
viru
strain
reason
antivir
resist
constantli
monitor
surveil
recent
guidanc
consult
latest
antivir
resist
profil
neuraminidas
inhibitor
neuraminidas
inhibitor
prevent
releas
new
virion
influenza
infect
cell
activ
influenza
boseltamivir
wide
avail
member
drug
class
use
children
adult
dose
oral
approv
treatment
prevent
influenza
avail
capsul
form
powder
suspens
although
suspens
rel
short
shelf
life
often
substanti
expens
capsul
result
capsul
wide
use
formul
oral
suspens
unavail
capsul
open
dilut
sweeten
liquid
provid
appropri
dosezanamivir
predominantli
avail
inhal
formul
although
intraven
zanamivir
avail
investig
use
particularli
sever
ill
patient
suspect
confirm
oseltamivirresist
viru
inhal
prepar
contraind
children
histori
wheez
chronic
respiratori
condit
use
recommend
children
younger
year
ageperamivir
intraven
neuraminidas
inhibitor
approv
use
children
wide
availableneuraminidas
inhibitor
gener
well
toler
common
side
effect
includ
nausea
vomit
rash
well
bronchospasm
zanamivir
neuropsychiatr
symptom
link
oseltamivir
use
particularli
japan
howev
recent
evid
suggest
caus
link
sever
advers
reaction
report
consid
rare
mainstay
influenza
prevent
remain
immun
high
risk
situat
amongst
partial
unimmun
children
chemoprophylaxi
consid
pre
postexposur
chemoprophylaxi
advoc
howev
concern
regard
induct
oseltamivirresist
temper
enthusiasm
approach
prophylact
use
increasingli
discouragedantivir
treatment
offer
soon
possibl
hospit
children
presum
confirm
influenza
influenza
sever
children
high
risk
sever
complic
influenza
tabl
time
oseltamivir
treatment
reduc
durat
fever
symptom
prospect
random
control
trial
treatment
efficaci
neuraminidas
inhibitor
hospit
children
sever
outcom
observ
data
suggest
treatment
reduc
risk
hospit
death
although
controversi
literatur
tabl
treatment
initi
earli
possibl
benefit
treatment
maxim
earli
cours
diseas
start
within
hour
symptom
onset
influenza
diagnosi
may
confirm
within
timefram
treatment
often
initi
empir
prior
microbiolog
confirm
evid
suggest
benefit
sever
ill
even
treatment
initi
later
hour
diseas
cours
therefor
patient
sever
complic
diseas
treatment
initi
even
hour
ill
onset
children
meet
clinic
criteria
treatment
treat
irrespect
whether
vaccinatedsinc
influenza
gener
mild
selflimit
diseas
previous
well
children
children
requir
antivir
treatment
even
present
soon
symptom
onset
treatment
children
increas
risk
advers
event
potenti
increas
risk
resist
develop
may
deplet
medicin
suppli
greater
need
adamantan
agent
target
influenza
protein
essenti
effici
viral
replic
activ
influenza
b
activ
current
circul
influenza
strain
use
current
recommend
treatment
prevent
influenza
suggest
may
role
combin
oseltamivir
treatment
oseltamivirresist
influenza
chang
natur
influenza
virus
world
health
organ
monitor
epidemiolog
influenza
virus
throughout
world
global
influenza
surveil
respons
system
gisr
separ
recommend
made
southern
hemispher
northern
hemispher
vaccin
strain
year
year
toward
end
influenza
season
recommend
strain
includ
vaccin
hemispher
follow
influenza
season
made
influenza
vaccin
given
person
wish
reduc
risk
becom
ill
influenza
season
countri
unit
state
america
usa
unit
kingdom
uk
recommend
influenza
vaccin
children
individu
addit
special
effort
made
vaccin
children
risk
sever
influenza
list
tabl
individu
healthcar
personnel
childcar
provid
especi
contact
infant
age
month
children
underli
risk
condit
vaccin
reduc
risk
transmiss
high
risk
children
lastli
pregnant
women
recommend
receiv
influenza
vaccin
reduc
risk
sever
ill
mother
provid
direct
protect
young
infant
transplacent
transfer
matern
antibodi
reduc
risk
transmiss
influenza
mother
young
infant
avail
mani
year
includ
inactiv
compon
two
influenza
one
influenza
pdm
influenza
one
influenza
b
strain
sinc
two
antigen
distinct
influenza
b
lineag
victoria
yamagata
circul
global
limit
protect
may
reduc
circul
influenza
b
strain
lineag
includ
includ
addit
strain
influenza
b
lineag
includ
tiv
make
total
four
strain
thu
potenti
offer
addit
benefit
protect
circul
influenza
b
lineag
inactiv
influenza
vaccin
contain
live
viru
standarddos
iiv
contain
haemagglutinin
antigen
ml
dose
avail
formul
intramuscular
im
intraderm
id
use
id
formul
licens
use
individu
age
year
older
two
formul
manufactur
use
technolog
includ
egg
becom
avail
recent
year
neither
licens
individu
age
year
cellcultur
base
inactiv
influenza
vaccin
recombin
influenza
vaccin
laiv
live
attenu
influenza
vaccin
administ
intranas
licens
use
individu
age
year
age
sinc
laiv
avail
quadrival
formul
adjuv
formul
influenza
vaccin
licens
use
individu
age
year
usa
current
children
shown
higher
efficaci
iiv
random
control
trial
children
adjuv
sever
potenti
advantag
tradit
vaccin
formul
includ
increas
immunogen
potenti
reduc
amount
antigen
requir
elicit
robust
immun
respons
could
potenti
reduc
number
dose
need
children
children
age
month
year
receiv
two
influenza
dose
administ
week
apart
first
time
influenza
vaccin
administ
young
children
requir
two
dose
influenza
vaccin
vaccin
delay
ensur
dose
given
product
licens
effect
influenza
vaccin
product
may
use
dose
import
document
dose
influenza
vaccin
administ
child
medic
record
temper
countri
influenza
vaccin
administ
soon
possibl
influenza
vaccin
becom
avail
recommend
dosag
influenza
vaccin
patient
differ
age
group
describ
tabl
influenza
vaccin
effect
depend
characterist
vaccin
age
health
whether
good
match
circul
virus
virus
contain
vaccin
influenza
type
subtyp
circul
year
gener
influenza
vaccin
work
best
among
children
year
healthi
adult
older
peopl
year
children
year
sever
immunocompromis
individu
often
poorer
immun
respons
inactiv
influenza
vaccin
iiv
compar
healthi
adult
howev
even
peopl
influenza
vaccin
still
provid
protect
product
eg
highdos
influenza
vaccin
adjuv
vaccin
shown
effect
certain
group
vaccin
may
avail
set
licens
use
age
group
number
studi
iiv
effect
children
age
month
season
iiv
young
children
two
dose
influenza
vaccin
provid
better
protect
one
dose
first
season
child
vaccin
estim
iiv
efficaci
young
children
limit
vari
season
studi
design
efficaci
lower
children
age
month
data
unclear
effect
hivinfect
children
age
year
random
control
trial
healthi
children
age
found
vaccin
effect
ci
sever
random
control
trial
observ
studi
demonstr
high
efficaci
laboratoryconfirm
influenza
studi
compar
efficaci
iiv
laiv
gener
found
laiv
similar
better
efficaci
iiv
sinc
replac
avail
laiv
licensur
basi
immunogen
studi
conflict
find
effect
laiv
emerg
differ
set
usa
withdraw
recommend
laiv
use
influenza
season
base
concern
reduc
effect
particularli
pdm
compon
vaccin
studi
europ
season
found
moder
laiv
effect
similar
iiv
year
recommend
laiv
remain
unchang
england
europ
vaccin
individu
risk
sever
influenza
may
provid
direct
protect
individu
addit
vaccin
individu
close
contact
peopl
risk
sever
influenza
may
provid
indirect
protect
prevent
transmiss
highrisk
individu
vaccin
children
protect
children
directli
gener
popul
indirectli
strategi
especi
import
individu
influenza
vaccin
indic
children
age
month
may
protect
matern
immun
random
control
trial
conduct
south
africa
shown
pregnant
women
receiv
influenza
vaccin
risk
develop
influenza
halv
risk
infant
first
week
life
vaccin
shown
efficaci
prevent
influenza
mother
infant
also
safe
vaccin
healthcar
worker
may
decreas
risk
spread
influenza
patient
recent
influenza
vaccin
preclud
diagnosi
influenza
vaccin
effect
larg
yeartoyear
variabl
influenza
vaccin
effect
depend
circul
influenza
strain
mani
countri
publish
annual
estim
influenza
vaccin
effect
use
testneg
casecontrol
studi
design
systemat
review
testneg
casecontrol
studi
found
pool
ci
type
b
suggest
reduc
protect
avail
vaccin
influenza
recent
year
iiv
inactiv
vaccin
wellestablish
safeti
record
safe
use
pregnanc
children
month
age
minor
ill
without
fever
contraind
influenza
vaccin
administr
clinician
alway
consult
manufactur
packag
insert
current
contraind
precaut
particular
product
contraind
administr
iiv
includ
histori
sever
anaphylact
hypersensit
compon
vaccin
includ
egg
protein
previou
dose
influenza
vaccin
anaphylaxi
rare
care
histori
distinguish
anaphylact
reaction
allerg
reaction
like
rash
mild
egg
protein
allergi
contraind
influenza
vaccineinf
month
age
precaut
iiv
administr
includ
person
moder
sever
ill
without
fever
prefer
immun
symptom
resolvedperson
develop
syndrom
within
week
receiv
influenza
vaccin
contraind
administr
laiv
includ
follow
children
year
age
histori
recurr
wheez
medic
attend
wheez
episod
previou
month
potenti
increas
wheez
immunizationchildren
diagnosi
asthmachildren
histori
egg
allergychildren
receiv
live
viru
vaccin
within
past
week
howev
live
viru
vaccin
given
day
laivchildren
known
suspect
immunodefici
diseas
receiv
immunosuppress
immunomodulatori
therapieschildren
receiv
aspirin
salicylatesani
femal
pregnant
consid
pregnancychildren
condit
compromis
respiratori
function
handl
secret
increas
risk
aspirationchildren
take
influenza
antivir
medic
oseltamivir
zanamivir
hour
stop
influenza
antivir
therapychildren
chronic
underli
medic
condit
may
predispos
complic
wildtyp
influenza
infect
vaccin
influenza
vaccin
administ
set
abil
respond
acut
hypersensit
reaction
appropri
hand
respiratori
hygien
cough
etiquett
shown
reduc
influenza
transmiss
children
daycar
school
sick
children
adult
remain
home
attend
school
work
symptom
resolv
prevent
transmiss
influenza
other
